Drugs / Murine autologous anti-CD19 chimeric antigen receptor T cells
Murine autologous anti-CD19 chimeric antigen receptor T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04325841 | Mar 2022 → Apr 2024 | childhood acute lymphoblastic leukemia | Beijing Boren Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Murine autologous anti-CD19 chimeric antigen receptor T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04325841 ↗ |
| Modality | Cell therapy | “autologous murine anti-CD19 chimeric antigen receptor T cells” NCT04325841 ↗ |